Making Moral Decisions on a Double-blinded Drug Trial in Progress without Breaking the Code

Allen D. Allen

Medical Decision Making, 1989, vol. 9, issue 3, 207-216

Abstract: The double blinding of drug trials to prevent bias deprives physicians of information they need in order to comply with their duty to treat patients and do them no harm. This ethical dilemma can be ameliorated with a standard statistical method known as posterior analysis. The clinical researcher can use posterior analysis to calculate the probability that a patient in a double-blinded drug trial is in the placebo group, based on the patient's clinical status. The clinician can also calculate the probability that the drug is safe and efficacious, as compared with the placebo, without breaking the code.

Keywords: Key words: medical ethics; medical economics; governmental regulation of drug companies; randomized double-blinded pla cebo-controlled clinical research; human experimentation; posterior analysis; Bayes' theo rem. (Med Decis Making 1989; 9:207-216) (search for similar items in EconPapers)
Date: 1989
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X8900900309 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:9:y:1989:i:3:p:207-216

DOI: 10.1177/0272989X8900900309

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().